This protocol allows patients who completed Coley oncology studies using PF-3512676 (CPG 7909) Injection to continue receiving the treatment until disease progression.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
31
PF-3512676 IV at doses: 0.01mg/kg, 0.16mg/kg and 0.32mg/kg PF-3512676 Injection given by subcutaneous injection at doses: 0.04mg/kg, 0.16mg/kg, 0.20mg/kg, 0.28mg/kg, 0.32mg/kg, 6mg, 10mg, 40mg.
Adverse Events and DLTs will be evaluated by the Investigator and summarized.
Time frame: indeterminate
No formal statistical analysis of this study will be conducted. All clinical data may be summarized and included in data listings.
Time frame: indeterminate
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Pfizer Investigational Site
Berkely, California, United States
Pfizer Investigational Site
Gilroy, California, United States
Pfizer Investigational Site
Hollister, California, United States
Pfizer Investigational Site
Los Angeles, California, United States
Pfizer Investigational Site
Los Angeles, California, United States
Pfizer Investigational Site
Palm Springs, California, United States
Pfizer Investigational Site
Stanford, California, United States
Pfizer Investigational Site
New Haven, Connecticut, United States
Pfizer Investigational Site
Bonita Springs, Florida, United States
Pfizer Investigational Site
Bradenton, Florida, United States
...and 22 more locations